| Literature DB >> 19038252 |
Joanna Riddoch-Contreras1, Shi-Yu Yang, James R T Dick, Geoffrey Goldspink, Richard W Orrell, Linda Greensmith.
Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by motoneuron degeneration. Although viral delivery of IGF-I has shown therapeutic efficacy in the SOD1(G93A) mouse model of ALS, clinical trials of IGF-I in ALS patients have led to conflicting results. Here we examine the effects of an IGF-I splice variant, mechano-growth factor (MGF) which has previously been shown to have greater neuroprotective effects than IGF-I in a number of models of neurodegeneration. A mammalian expression plasmid containing either MGF or, for comparison, the IGF-I cDNA sequence was delivered to the hindlimb muscles of SOD1(G93A) mice at 70 days of age, at symptom onset. Treatment with either IGF-I or MGF resulted in a significant improvement in hindlimb muscle strength, and an increase in motor unit and motoneuron survival. Significantly more motoneurons survived in MGF treated mice.Entities:
Mesh:
Substances:
Year: 2008 PMID: 19038252 DOI: 10.1016/j.expneurol.2008.10.014
Source DB: PubMed Journal: Exp Neurol ISSN: 0014-4886 Impact factor: 5.330